Condition
Cervical Intraepithelial Neoplasia 3
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 1 (1)
Trial Status
Unknown3
Completed1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03958240Not ApplicableRecruiting
Deciphering Mechanisms Underlying Cancer Immunogenicity
NCT02100085UnknownPrimary
Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation
NCT02411019UnknownPrimary
Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation
NCT03206138Not ApplicableUnknownPrimary
Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.
NCT01634503Phase 1CompletedPrimary
Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3
Showing all 5 trials